What the Wegovy pill trial found — and what it means for you

Step 1: understanding how the trial was set up

OASIS 4 was a randomised, double-blind, placebo-controlled phase 3 trial. Novo Nordisk recruited 307 adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure or raised cholesterol. Participants did not have type 2 diabetes, a deliberate design choice, to isolate weight-management outcomes from any glucose-lowering effect.

The trial ran for 64 weeks. Participants were assigned either oral semaglutide or placebo, both taken alongside lifestyle guidance covering reduced calorie intake and increased physical activity. This lifestyle component matters: the numbers reflect what the medicine adds on top of structured support, not the medicine alone. Our overview of what the oral Wegovy format involves explains the daily routine that makes adherence possible.

The dose escalation followed the licensed schedule: starting at 1.5 mg daily, increasing through 4 mg and 9 mg to a 25 mg maintenance dose, with at least one month at each step. That gradual ramp is designed to let the body adjust and keep GI side effects manageable.

Step 2: reading the results accurately

The headline figure from OASIS 4 is a mean weight reduction of approximately 13.6% in the semaglutide group versus around 2.4% in the placebo group, based on all participants regardless of how consistently they took their medication. That is the number to quote as the trial average, and it is the figure the MHRA weighed when approving the tablet in June 2026, regulatory approval announcements from GOV.UK confirm the broad clinical programme underpinning semaglutide's weight-management licence.

A second figure, around 16.6%, applies specifically to participants who adhered fully throughout the study. That is a meaningful data point but a different one: it tells you what the treatment tends to deliver when people take it as prescribed, which is obviously the more optimistic scenario. Both numbers appear in the published evidence; neither should be used to predict any individual's outcome.

For context on how these results sit relative to the injectable form, our page on semaglutide tablets covers the comparison between oral and injected semaglutide in plain terms. The injectable Wegovy pen reached around 15% average weight loss in STEP 1 (68 weeks, 2.4 mg weekly), as noted by the NHS medicines information on semaglutide. The oral tablet's 13.6% average over a slightly shorter follow-up period is genuinely close.

Step 3: what the side-effect profile looked like in practice

Gastrointestinal events dominated. Roughly 74% of participants on oral semaglutide reported at least one GI event across the trial, against 42% in the placebo group. Nausea, diarrhoea, constipation and indigestion were the most common. The pattern will be familiar to anyone who has read about GLP-1 medicines generally: symptoms tend to peak after starting or stepping up a dose, then ease off over days to a couple of weeks as the body adjusts.

The trial characterised most events as mild to moderate in severity. Discontinuations due to GI side effects did occur but were not the majority experience. Serious adverse events were low in frequency and broadly comparable between groups. The slow dose-escalation schedule exists precisely to reduce this burden, patients who try to rush the titration tend to find the side effects much harder to manage.

One practical note our prescribers hear often: the morning routine for this tablet is strict. Empty stomach, plain water only, then a wait of at least 30 minutes before anything else passes your lips, including the first coffee of the day. Think of it as a tablet that goes in before the kettle goes on. Getting that habit right is closely linked to both tolerability and the absorption the trial assumed. More detail on the practical side is covered on our page about oral Wegovy.

Who the trial population maps to, and what the licence actually says

OASIS 4 enrolled adults who fit the licensed population: BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition, no type 2 diabetes. The MHRA licence mirrors that eligibility profile. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance.

The NHS does not currently fund this tablet; a NICE appraisal would be required before any NHS commissioning. That means access at the moment is through a private prescription following clinical assessment. You can find an outline of your options on our weight-loss treatments overview, or if you want to know more about what makes a reputable online pharmacy, our about us page sets out how clinical oversight works at a GPhC-registered service.

For a straightforward breakdown of what the treatment costs privately, the semaglutide tablets pricing page sets out the context honestly. The most important thing the trial data cannot tell you is whether this treatment suits your specific health picture, and if you are curious whether taking Wegovy as a pill rather than an injection might be the right fit for you, that is also a question worth raising with our prescribers during your clinical assessment.